Furthermore, polymorphisms of RIPK1 have been found to be associated with differences in disease progression and correlated with overall survival and disease-free survival [101], suggesting that evaluation of RIPK1 polymorphism may be useful as a prognostic biomarker for tumor development. The gene discussed is RIPK1; the disease is neoplasm.